Form 4 for IMNM Immunome Inc.
Accepted 2024-05-21 00:00:00 ET · period of report 2024-05-20 · accession 0001415889-24-013935 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-05-21 | 2024-05-20+ | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | P - Purchase | $13.88 | +100.0K | 419.6K | +31% | +$1.39M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-20 | P | A | 79,566 | $13.91 | 399,202 | D | — | — | (F1) The weighted average purchase price for the transaction report was $13.907,and the range of prices were between $13.77 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |
| 2 | Common | Common Stock | 2024-05-21 | P | A | 20,434 | $13.78 | 419,636 | D | — | — | (F2) The weighted average purchase price for the transaction report was $13.7784, and the range of prices were between $13.62 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |